MedTrace Logo

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

NCT02873962 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-01

Study results available
· View outcomes & findings →

Summary

This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

Conditions

Interventions

DRUG

Bevacizumab

* Bevacizumab will be given intravenously at a pre-determined dosage * One dose reduction will be allowed for Bevacizumab

DRUG

Nivolumab

* Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage. * No dose reductions or escalations will be allowed for Nivolumab

DRUG

Rucaparib

* Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage. * Up to three dose reductions will be allowed for Rucaparib (depending on cohort).

Sponsors & Collaborators

Principal Investigators

  • Joyce Liu, MD MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-10
Primary Completion
2025-02-28
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02873962 on ClinicalTrials.gov